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Abstract 
The FABP5 gene encodes a member of the fatty acid 
binding protein family which is also known as 
epidermal or cutaneous FABP. Overexpression of 
FABP5 is associated with a number of cancers 
including breast and prostate cancers, as well as 
psychiatric disorders and diabetes. FABP5 can bind 
retinoic acid as well as polyunsaturated and saturated 
fatty acids. Transport of FABP5 ligands such as 
arachidonic acid and retinoic acid to the nucleus is 
believed to activate the nuclear receptor peroxisome 
proliferator-activated receptor beta/delta (PPARβ/δ). 
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Identity 
Other names: E-FABP, EFABP, KFABP, PA-
FABP, PAFABP 
HGNC (Hugo): FABP5 
Location: 8q21.13 
Local order: PAG1 → FABP5 → PMP2. 
DNA/RNA 
Description 
The FABP5 gene spans approximately 4.3 kb and 
has 4 exons, all of which contain coding sequences. 
Ten SNPs have been validated in the coding region 
of FABP5, 7 missense and 3 synonymous (not 
affecting the amino acid sequence).  
Two SNPs in the regulatory region of FABP5 have 
been identified in association with type 2 diabetes 
mellitus (T2DM): rs454550 showed significant 
association with T2DM in a non-Hispanic White 
sample, and a newly reported SNP at genomic 
position 82354416 was associated with T2DM in 
both non-Hispanic White and African sample 
populations (Bu et al., 2011).  
A missense 340G>C (Gly114Arg) SNP in the coding 
region of FABP5 has been linked to autism 
(Maekawa et al., 2010). FABP5 SNPs are described 
at the following site 
(http://www.ncbi.nlm.nih.gov/snp). 
Transcription 
The transcript is approximately 750 nucleotides with 
an open reading frame of 408 nucleotides, a 5' 
untranslated region of 113 nucleotides and a 3' 
untranslated region of 209 nucleotides excluding the 
poly-A tail. 
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FABP 5 gene. The FABP5 gene is located on chromosome 8 in the region of q21.13 on the positive strand. Neighbouring genes 
are indicated. 
Based on Expressed Sequence Tag (EST) data, 
FABP5 RNA is present in a wide range of human 
tissues, with highest levels in the uterus, pharynx, 
bone, and heart. FABP5 transcripts have been 
identified in normal mammalian cells, including 
adipocytes, tongue epithelia, lens (Wen et al., 1995), 
developing retina, lung and mammary gland 
epithelia (Zimmerman and Veerkamp, 2002), 
macrophages, kidney, liver, and skeletal muscle 
(Smathers and Petersen, 2011). 
Immunohistochemistry has confirmed the presence 
of FABP5 in endothelial cells of the placenta, heart, 
small intestine, and renal medulla (Masouyé et al., 
1997). 
Nerve growth factor (NGF) positively regulates 
FABP5 expression in PC12 cells 
(pheochromocytoma of rat adrenal medulla) through 
a MEK-dependent pathway (Liu et al., 2008). 
FABP5 is a known target of c-Myc (Coller et al., 
2000), and epithelial cell adhesion molecule epCAM 
has been demonstrated to upregulate FABP5 
expression, presumably via induction of c-Myc 
(Münz et al., 2005).  
The promoter region of FABP5 contains two cognate 
response elements (CREs) to transcription factor 
NF-κB (Kannan-Thulasiraman et al., 2010). 
Epidermal growth factor receptor (EGFR) activation 
directly increases FABP5 expression through the 
ERK and phosphatidylinositol-3-kinase cascades 
and subsequent activation of NF-κB (Kannan-
Thulasiraman et al., 2010).  
Ligands of peroxisome proliferator-activated 
receptors (PPARs) have been shown to influence 
FABP5 expression: PPARα and PPARγ agonists 
upregulate FABP5 expression, whereas PPARβ 
activation decreases FABP5 expression (Hyder et 
al., 2010). In contrast to FABP7, mRNA length for 
FABP5 does not vary throughout the body, limiting 
the likelihood of post-transcriptional modification 
(Zimmerman and Veerkamp, 2002). 
Pseudogene 
The human genome contains 14 pseudogenes similar 
to the FABP5 locus. 
Predicted pseudogenes are listed here: 
http://www.ncbi.nlm.nih.gov/gene/?Term=related_f
unctional_gene_2171%5Bgroup%5D. 
Protein 
Description 
FABP5 is a member of the intracellular lipid binding 
protein family. FABP5 is a 135 amino acid protein 
with an estimated molecular mass of 15.1 kDa. 
Similar to other FABPs, FABP5 has a beta-clam 
(beta barrel) structure composed of 10 anti-parallel 
beta sheets and two N-terminal alpha helices, with 
low backbone motility (Gutiérrez-González et al., 
2002). Six cysteine residues and a disulfide bridge 
between Cys120 and Cys127 contribute to protein 
stability and are hypothesized to relieve oxidative 
stress by thiol disulfide interchange reaction (Odani 
et al., 2000). Hydrophobic ligands are bound within 
the water-filled central cavity formed by the beta 
barrel. The carboxylic head group of linoleic acid 
forms a salt bridge with Arg-129 and hydrogen 
bonds with the hydroxyl groups of Tyr-131 and Arg-
109 in the binding pocket of FABP5 (Armstrong et 
al., 2014). Hydrophobic residues within the binding 
pocket such as Cys-120 also facilitate ligand 
binding. FABP5 contains ligand-sensitive tertiary 
nuclear  
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localization sequences in the α1 and α2 helices and a 
putative nuclear export signal located at the edge of 
the β-barrel. The putative NES consists of Lys-69, 
Lys-94, and Phe-89 residues (Armstrong et al., 
2014). 
Expression 
FABP5 was first identified as a low molecular 
weight protein highly upregulated in human psoriatic 
skin (Madsen et al., 1992). FABP5 is expressed in 
numerous normal adult epithelial tissues, including 
those of the reproductive and urinary tracts, 
mammary glands, lungs, tongue, and lens. FABP5 is 
also expressed in macrophages, bone, and skeletal 
muscle (Smathers and Petersen, 2011). The 
expression of FABP5 during mammalian 
neurogenesis has been investigated using rodent 
models, with similar results obtained in mouse and 
rat. FABP5 transcripts are detected in mid-term 
embryonic rat brain, peaking at birth and gradually 
decreasing from P1 to P21, with expression virtually 
undetectable in the adult brain (Owada et al., 2002), 
except during regeneration in response to neuronal 
injury (Allen et al., 2001). FABP5 is critical in post-
natal hippocampal dentate gyrus neurogenesis in 
mice (Matsumata et al., 2012). 
Localisation 
The FABP5 protein has a nuclear or cytoplasmic 
localization that is dependent upon ligand binding 
and cell type. Retinoic acid (RA), linoleic acid and 
arachidonic acid (AA) have been shown to elicit 
nuclear translocation through allosteric interaction 
between the ligand-sensing β2 loop and nuclear 
localization sequence (NLS) in the alpha helix (Tan 
et al., 2001; Schug et al., 2007; Armstrong et al., 
2014). 
Function 
Unique to brain-expressed FABPs, both human and 
rat FABP5 have a high affinity for saturated fatty 
acids such as stearic acid, with a Kd of 168.1 nM as 
determined by 1-anili-nonapthalene-8-sulfonic acid 
(ANS) assay (Liu et al., 2010), and 290 nM as 
determined by the Lipidex assay (see Table) (Liu et 
al., 2010). FABP5 has a broad range of saturated and 
unsaturated hydrophobic ligands, including linoleic 
acid, eicosapentanenoic acid (EPA), 
docosahexaenoic acid (DHA), AA and their 
derivatives (Sanson et al., 2014). Nuclear 
localization upon binding to linoleic acid and AA is 
thought to influence gene expression through 
activation of the nuclear receptor PPARβ/δ (Tan et 
al., 2001), which controls the expression of genes 
involved in lipid and glucose metabolism, 
differentiation, and survival (Schug et al., 2007). 
FABP5 expression during development is associated 
with neurite outgrowth (Allen et al., 2001), with an 
important role in post-natal hippocampal dentate 
gyrus neurogenesis through nuclear transport of RA 
to activate PPARβ/δ (Matsumata et al., 2012). The 
hippocampi of FABP5-null mice contain excess 
neuronal progenitors and are deficient in mature 
neurons (Yu et al., 2012). FABP5 knockout mice do 
not have a brain phenotype, perhaps as a result of 
compensation by other FABP members. 
FABP5 has been shown to facilitate nociception in 
mice through transport of adandamide (AEA), an 
anti-nociceptive lipid that is hydrolyzed into AA 
within the cell. FABP5 knockout mice accumulate 
AEA, which results in PPARβ/δ inactivation (Yu et 
al., 2014). Pharmacological inhibition of FABP5 
reduces inflammatory, visceral, and neuropathic 
pain in mice (Kaczocha et al., 2014). 
FABP5 knockout mice exhibit reduced basal 
transepithelial water loss (TEWL) and delayed 
recovery in TEWL upon disruption of the lipid 
barrier, suggesting that FABP5 plays a critical role 
in maintenance of the water permeability barrier of 
the skin (Owada et al., 2002). 
Several cell types in the immune system, including 
macrophages, thymic epithelial cells, and subsets of 
lymphocytes express FABP5, and animal studies 
indicate that FABP5 plays a role in immune 
regulation (Grau et al., 2003; Adachi et al., 2012). 
Production of cytokines IL-7 and IL-18 is increased 
in stromal cells over-expressing FABP5 (Adachi et 
al., 2012), while ablation of FABP5 results in 
increased macrophage and neutrophil infiltration 
during influenza A infection (Gally et al., 2013). 
Lung epithelial cells initially downregulate FABP5 
expression during the onset of the anti-viral 
response, and recover pre-infection levels upon 
attenuation of inflammation. Deficiency in FABP5 
correlates with increased oxidative damage and lipid 
peroxidation over the course of infection, indicating 
that FABP5 is required for the prevention of tissue 
damage resulting from excessive inflammation 
(Gally et al., 2013). 
Homology 
The human FABP5 amino acid sequence is 64.8% 
identical to chicken FABP5 and 80% identical to 
mouse FABP5 isoform 1. Human FABP5 shows 
variable sequence identity with the other FABP 
paralogues, with the highest identity to 
FABP8/PMP2 (59%) and the lowest identity to 
FABP2 and FABP6 (27%). FABP5 is 
phylogenetically related to FABP3 and FABP7, 
which are also expressed in the brain (Schoentgen et 
al., 1989; Godbout, 1993; Bennett et al., 1994; Feng 
et al., 1994) and shows 51% and 46% amino acid 
sequence identity with FABP3 and FABP7, 
respectively. FABP5 also has sequence identity to 
other lipid binding proteins, with 36% identity to 
human cellular retinoic acid binding protein 1 
(CRABP1). 
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Ligand affinities for FABP5. Abbreviations: Rn= Rattus norvegicus, Ms= Mus musculus, Hs= Homo sapiens. 
Mutations 
Note 
Several variants of FABP5 have been linked to 
human diseases, including type 2 diabetes. Nine 
MGI mutant phenotypes in mice have been reported, 
with disruption in FABP5 resulting in defects in 
epithelial water balance and resistance to obesity. 
Implicated in 
Cancer 
FABP5 is involved in signaling pathways controlling 
differentiation, metabolism, proliferation, and 
resistance to apoptosis (Tan et al., 2001) and is 
highly expressed in several human tumors including 
breast, prostate, oral, and hepatocellular carcinomas 
(Adamson et al., 2003; Fujii et al., 2005; Fang et al., 
2010). The majority of malignancies associated with 
elevated FABP5 are of apparent epithelial origin, 
where FABP5 is believed to contribute to 
proliferation, metastasis, and resistance to therapy. 
Breast cancer 
In 2001, FABP5 overexpression was shown to 
induce metastasis in rat mammary epithelial cells  
through induction of the vascular endothelial growth 
factor (VEGF) (Jing et al., 2001). FABP5 can also be 
upregulated by EGFR signaling in breast cancer cells 
and serves as a critical mediator of EGFR-induced 
cell proliferation (Kannan-Thulasiraman et al., 
2010). Analysis of a cohort of 120 breast cancer 
patients revealed an association between elevated 
levels of cytoplasmic FABP5, high tumor grade, 
reduced recurrence-free survival and poor prognosis 
in triple-negative breast cancer (Liu et al., 2011) (see 
Figure). Recently, genetic ablation of FABP5 was 
shown to suppress Her-2-induced mammary 
tumorigenesis, indicating a potential role for FABP5 
as a chemotherapeutic target (Levi et al., 2013). 
Manipulation of FABP5 levels in human breast 
cancer cell lines and cell lines generated from breast 
cancer mouse models demonstrates a correlation 
between FABP5 levels and response to RA treatment 
(Schug et al., 2007; Schug et al., 2008; Liu et al., 
2011). It has been hypothesized that FABP5 confers 
resistance to RA therapy through competition with 
CRABP2 for RA, with FABP5 promoting 
proliferation and survival through activation of 
PPARβ and CRABP2 inhibiting proliferation 
through activation of the nuclear retinoic acid 
receptor (RAR) (Schug et al., 2007; Schug et al., 
2008; Liu et al., 2011). 
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FABP5 mRNA levels in molecular and histological subtypes of breast cancer based on gene profiling data. FABP5 
mRNA levels were determined by gene expression microarray analysis of 176 treatment-naïve primary human breast tumors. 
Signal intensity values were normalized and log-transformed. Statistically significant differences between groups (indicated by 
stars) were determined using the student t-test. ** denotes p <0.01. 
Prostate cancer 
Elevated FABP5 protein levels are linked to 
increased tumor size and invasiveness in prostate 
cancer (Adamson et al., 2003). Depletion of FABP5 
decreases VEGF and microvessel density in prostatic 
tumors in nude mice and suppresses proliferation 
and invasion in prostatic carcinoma cells (Adamson 
et al., 2003). High levels of FABP5 are associated 
with a poorer prognosis in prostate cancer (Morgan 
et al., 2008; Forootan et al., 2014). Significantly 
higher levels of FABP5 protein were found in the 
serum of patients with lymph node metastatic 
prostate cancer compared to patients with localized 
prostate cancer (Pang et al., 2010). As in other 
cancers, FABP5 appears to influence tumor 
progression through PPARβ, and levels of both 
FABP5 and PPARβ correlate with the tumorigenic 
potential of prostate cancer cell lines by inducing the 
expression of genes which promote anchorage 
independence and proliferation (Morgan et al., 
2008). FABP5 has been shown to be a direct target 
of PPARβ in prostate cancer cell lines and it has been 
suggested that targeting the PPARβ/FABP5 pathway 
may represent a new strategy for the treatment of 
prostate cancer (Morgan et al., 2008). 
Other cancers 
FABP5 is elevated in several other human 
malignancies where it influences tumorigenic 
potential by modulating proliferation, invasion, and 
drug resistance.  
Cytoplasmic FABP5 levels are elevated in human 
head and neck squamous cell carcinomas (Han et al., 
2009). Elevated cytoplasmic FABP5 levels have also 
been documented in advanced tongue carcinomas 
(Ohyama et al., 2014).  
Proteomic analysis revealed FABP5 as highly 
upregulated in oral squamous cell carcinoma 
(OSCC). Overexpression of FABP5 increased 
invasion, proliferation and production of matrix 
metalloproteinase-9 (MMP-9) in OSCC cell lines 
(Fang et al., 2010). Drug-resistant adenocarcinoma 
of the pancreas is associated with high levels of 
FABP5, with FABP5 proposed to facilitate the 
sequestration and removal of cytotoxic drugs in 
these tumors (Sinha et al., 1999). In keeping with 
other types of cancers, a high ratio of FABP5 to 
CRABP2 in pancreatic ductal adenocarcinoma cell 
lines correlates with poor response to RA, whereas 
CRABP2 expression in the absence of FABP5 
correlates with growth inhibition in the presence of 
RA (Gupta et al., 2012). 
A number of RA signaling proteins, including 
FABP5, are highly expressed in high-grade 
astrocytomas, with FABP5 expression correlating 
with an undifferentiated tumor phenotype (Campos 
et al., 2011). The ratio of FABP5 to CRABP2 was 
found to correlate with survival time in grade IV 
astrocytoma patients, with a high FABP5 to 
CRABP2 ratio associated with shorter term survival 
(Barbus et al., 2011). 
Psychiatric diseases 
Abnormalities in lipid metabolism are linked to 
several psychiatric illnesses. Several rare non-
synonymous polymorphisms in FABP5 have been 
identified in patients with schizophrenia and autism 
spectrum disorder. Altered FABP5 mRNA 
expression levels were detected in schizophrenic 
brain (Shimamoto et al., 2014). Variants in the 
FABP5 gene were found in autistic patients, but no 
significant genetic association between FABP5 and 
autism has been established (Maekawa et al., 2010). 
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Obesity, metabolic syndrome, 
atherosclerosis 
Due to their role in lipid homeostasis, FABPs have 
been implicated in obesity, metabolic syndrome, and 
atherosclerosis. Increased serum levels of FABP5 
correlate with age, waist circumference, blood 
pressure, and insulin resistance in human adults 
(Ishimura et al., 2013). Combined deficiency in 
FABP5 and FABP4 in mice protects against 
atherosclerosis and metabolic syndrome (Babaev et 
al., 2011). In a population study of 806 individuals 
with type 2 diabetes, levels of FABP4 and FABP5 in 
adipocytes and macrophages independently 
correlated with incidence of metabolic syndrome and 
the presence of coronary artery calcium, a marker for 
coronary heart disease (Bagheri et al., 2010). FABP4 
and FABP5 may contribute to the pathogenesis and 
serve as biomarkers for metabolic syndrome and 
cardiovascular disease risk factors. 
Diabetes 
Two single nucleotide polymorphisms in the 
regulatory region of FABP5 are associated with type 
2 diabetes in humans (Bu et al., 2011). Human islet 
cells and insulin-secreting rat INS1E β-cells express 
FABP5 (Hyder et al., 2010). Targeted depletion of 
FABP5 protected mice from insulin resistance and 
diabetes when administered a high fat diet (Maeda et 
al., 2005). High glucose increased FABP5 
expression in human islet and rat β-cells, indicating 
that FABP5 contributes to pancreatic function and 
glucose metabolism in mammals (Hyder et al., 
2010). 
Psoriasis 
FABP5 was first identified as a gene highly 
upregulated in human psoriatic skin lesions (Madsen 
et al., 1992). Psoriasis is caused by a defect in the 
differentiation of keratinocytes, and FABP5 
modulates differentiation of normal and psoriatic 
human keratinocytes (Dallaglio et al., 2013). It has 
been proposed that FABP5 overexpression 
contributes to the pathogenesis of psoriasis by 
promoting the proliferation and survival of 
keratinocytes and disrupting the uptake and 
metabolism of fatty acids in the epidermis. In 
psoriasis patients, depletion of FABP5 in the 
epidermis upon TNF-α or narrow-band ultraviolet B 
treatment corresponded with response to therapy 
(Miyake et al., 2012). 
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